290 related articles for article (PubMed ID: 18757425)
21. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells.
García-Aragoncillo E; Carrillo J; Lalli E; Agra N; Gómez-López G; Pestaña A; Alonso J
Oncogene; 2008 Oct; 27(46):6034-43. PubMed ID: 18591936
[TBL] [Abstract][Full Text] [Related]
22. EWS-FLI1 and Ewing's sarcoma: recent molecular data and new insights.
Ladanyi M
Cancer Biol Ther; 2002; 1(4):330-6. PubMed ID: 12432241
[TBL] [Abstract][Full Text] [Related]
23. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors.
Joo J; Christensen L; Warner K; States L; Kang HG; Vo K; Lawlor ER; May WA
PLoS One; 2009 Oct; 4(10):e7608. PubMed ID: 19859563
[TBL] [Abstract][Full Text] [Related]
24. EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model.
Lin PP; Pandey MK; Jin F; Xiong S; Deavers M; Parant JM; Lozano G
Cancer Res; 2008 Nov; 68(21):8968-75. PubMed ID: 18974141
[TBL] [Abstract][Full Text] [Related]
25. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.
Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK
Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
[TBL] [Abstract][Full Text] [Related]
27. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A.
Toretsky JA; Erkizan V; Levenson A; Abaan OD; Parvin JD; Cripe TP; Rice AM; Lee SB; Uren A
Cancer Res; 2006 Jun; 66(11):5574-81. PubMed ID: 16740692
[TBL] [Abstract][Full Text] [Related]
28. Recombinant EWS-FLI1 oncoprotein activates transcription.
Uren A; Tcherkasskaya O; Toretsky JA
Biochemistry; 2004 Oct; 43(42):13579-89. PubMed ID: 15491164
[TBL] [Abstract][Full Text] [Related]
29. EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin.
Siligan C; Ban J; Bachmaier R; Spahn L; Kreppel M; Schaefer KL; Poremba C; Aryee DN; Kovar H
Oncogene; 2005 Apr; 24(15):2512-24. PubMed ID: 15735734
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of platelet-derived growth factor-induced cell growth signaling by a short interfering RNA for EWS-Fli1 via down-regulation of phospholipase D2 in Ewing sarcoma cells.
Nozawa S; Ohno T; Banno Y; Dohjima T; Wakahara K; Fan DG; Shimizu K
J Biol Chem; 2005 Jul; 280(30):27544-51. PubMed ID: 15919668
[TBL] [Abstract][Full Text] [Related]
31. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma.
Lin PP; Brody RI; Hamelin AC; Bradner JE; Healey JH; Ladanyi M
Cancer Res; 1999 Apr; 59(7):1428-32. PubMed ID: 10197607
[TBL] [Abstract][Full Text] [Related]
32. EWS/FLI1 suppresses retinoblastoma protein function and senescence in Ewing's sarcoma cells.
Hu HM; Zielinska-Kwiatkowska A; Munro K; Wilcox J; Wu DY; Yang L; Chansky HA
J Orthop Res; 2008 Jun; 26(6):886-93. PubMed ID: 18271016
[TBL] [Abstract][Full Text] [Related]
33. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma.
Owen LA; Kowalewski AA; Lessnick SL
PLoS One; 2008 Apr; 3(4):e1965. PubMed ID: 18414662
[TBL] [Abstract][Full Text] [Related]
34. Single-chain antibodies to the EWS NH(2) terminus structurally discriminate between intact and chimeric EWS in Ewing's sarcoma and interfere with the transcriptional activity of EWS in vivo.
Aryee DN; Kreppel M; Bachmaier R; Uren A; Muehlbacher K; Wagner S; Breiteneder H; Ban J; Toretsky JA; Kovar H
Cancer Res; 2006 Oct; 66(20):9862-9. PubMed ID: 17047047
[TBL] [Abstract][Full Text] [Related]
35. Notch signalling is off and is uncoupled from HES1 expression in Ewing's sarcoma.
Bennani-Baiti IM; Aryee DN; Ban J; Machado I; Kauer M; Mühlbacher K; Amann G; Llombart-Bosch A; Kovar H
J Pathol; 2011 Nov; 225(3):353-63. PubMed ID: 21984123
[TBL] [Abstract][Full Text] [Related]
36. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
Grohar PJ; Griffin LB; Yeung C; Chen QR; Pommier Y; Khanna C; Khan J; Helman LJ
Neoplasia; 2011 Feb; 13(2):145-53. PubMed ID: 21403840
[TBL] [Abstract][Full Text] [Related]
37. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.
Rao DD; Jay C; Wang Z; Luo X; Kumar P; Eysenbach H; Ghisoli M; Senzer N; Nemunaitis J
Mol Ther; 2016 Aug; 24(8):1412-22. PubMed ID: 27166877
[TBL] [Abstract][Full Text] [Related]
38. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.
Hahm KB; Cho K; Lee C; Im YH; Chang J; Choi SG; Sorensen PH; Thiele CJ; Kim SJ
Nat Genet; 1999 Oct; 23(2):222-7. PubMed ID: 10508522
[TBL] [Abstract][Full Text] [Related]
39. Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma.
Ban J; Aryee DN; Fourtouna A; van der Ent W; Kauer M; Niedan S; Machado I; Rodriguez-Galindo C; Tirado OM; Schwentner R; Picci P; Flanagan AM; Berg V; Strauss SJ; Scotlandi K; Lawlor ER; Snaar-Jagalska E; Llombart-Bosch A; Kovar H
Cancer Res; 2014 Nov; 74(22):6578-88. PubMed ID: 25281719
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G
Zöllner SK; Selvanathan SP; Graham GT; Commins RMT; Hong SH; Moseley E; Parks S; Haladyna JN; Erkizan HV; Dirksen U; Hogarty MD; Üren A; Toretsky JA
Sci Signal; 2017 Oct; 10(499):. PubMed ID: 28974650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
